Ani Pharmaceuticals Inc. diskutieren

ANI PHARMACEUTICALS INC. BUY

Kurzfristig (3 Monate) rechne ich mit 25% Kursanstieg, langfristig (>6 Monate) sind auch 50% durchaus drin.
http://www.followthetrend.eu/charts.php?sym=ANIP

10.2.2015: Kursziel erreicht, wir erhöhen das Kursziel auf 55€.

ANIP STRONG BUY

ANIP sollte in den nächsten Tagen die Marke von 75$ knacken, und in 6 Monaten die 100$ erreichen.

http://www.followthetrend.eu/charts.php?sym=ANIP

tamam stimmt der fundamentalen Bewertung mit dem Ergebnis 'unterbewertet' zu

This company develops, manufactures and markets both branded and generic
prescription drugs. This under covered drug play is headquartered in
Minnesota and has a market capitalization of approximately $550 million.
ANI Pharmaceuticals is pursuing a well-rounded approach that meshes
accretive acquisitions with internal product development. This strategy
has delivered impressive earnings and revenue growth for several years
and I expect that to continue into the foreseeable future.

Revenues are currently tracking to 50% growth year-over-year. Depending
on new product rollout, the company should post another 40% increase in
sales in FY2014. After posting earnings of just over $1.10 a share in
FY2014, the current consensus has ANI earning $2.40 to $2.50 a share
this year and over $3.25 a share in FY2016. The company has a solid
balance sheet and the stock goes for just over 15 times next year's
expected profits. That is right in line with the overall market multiple
despite ANI's far superior growth prospects.

ani pharm

Codeinphosphat; Promethazinhydrochlorid Sirup; Oral EXTRA-33 Ani Pharms Kennzeichnung genehmigt

Codeinphosphat; Promethazinhydrochlorid Sirup; Oral EXTRA-33 Ani Pharms Kennzeichnung genehmigt

SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats

Engages in the developing, manufacturing, and marketing branded and generic prescription pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.

The company was founded on August 29, 1996 and is headquartered in Baudette, MN.